Affiliation:
1. Department of Neurology, Institute of Translational Neurology University of Münster Münster Germany
Abstract
AbstractDemyelination of corticospinal tract neurons contributes to long‐term disability after cortical stroke. Nonetheless, poststroke myelin loss has not been addressed as a therapeutic target, so far. We hypothesized that an antibody‐mediated inhibition of the Nogo receptor‐interacting protein (LINGO‐1, leucine‐rich repeat and immunoglobulin domain‐containing Nogo receptor‐interacting protein) may counteract myelin loss, enhance remyelination and axonal growth, and thus promote functional recovery following stroke. To verify this hypothesis, mice were subjected to photothrombotic stroke and received either an antibody against LINGO‐1 (n = 19) or a control treatment (n = 18). Behavioral tests were performed to assess the effects of anti‐LINGO‐1 treatment on the functional recovery. Seven weeks after stroke, immunohistochemical analyses were performed to analyze the effect of anti‐LINGO‐1 treatment on myelination and axonal loss of corticospinal tract neurons, proliferation of oligodendrocytes and neurogenesis. Anti‐LINGO‐1 treatment resulted in significantly improved functional recovery (p < 0.0001, repeated measures analysis of variance), and increased neurogenesis in the hippocampus and subventricular zone of the ipsilateral hemisphere (p = 0.0094 and p = 0.032, t‐test). Notably, we observed a significant increase in myelin (p = 0.0295, t‐test), platelet‐derived growth factor receptor α‐positive oligodendrocyte precursor cells (p = 0.0356, t‐test) and myelinating adenomatous polyposis coli‐positive cells within the ipsilateral internal capsule of anti‐LINGO‐1‐treated mice (p = 0.0021, t‐test). In conclusion, we identified anti‐LINGO‐1 as the first neuroregenerative treatment that counteracts poststroke demyelination of corticospinal tract neurons, presumably by increased proliferation of myelin precursor cells, and thereby improves functional recovery. Most importantly, our study presents myelin loss as a novel therapeutic target following stroke.